с обл мал

‘9 (101) декабрь 2016 г.
ПРАКТИЧЕСКАЯ МЕДИЦИНА 117
30. Tzoulaki I., Molokha M., Curcin V., et al. Risk of cardiovascular
disease and all cause mortality among patients with type 2 diabetes
prescribed oral antidiabetes drugs: retrospective cohort study using
UK general practice research database // BMJ. ― 2009. ― №339. ―
b4731.
31. Roussel R. et al. Thiazolidinedione use is not associated with
worse cardiovascular outcomes: a study in 28,332 high risk patients
with diabetes in routine clinical practice: brief title: thiazolidinedione
use and mortality // Int. J. Cardiol. ― 2013. ― №4. ― Р. 1380-1384.
32. Lu C.J., Sun Y., Muo C.H., et al. Risk of stroke with
thiazolidinediones: a ten-year nationwide population-based cohort
study // Cerebrovasc Dis. ― 2013. ― №2. ― Р. 145-151.
33. James J. DiNicolantonio, Jaikrit Bhutani and James H. O'Keefe.
Acarbose: safe and effective for lowering postprandial hyperglycaemia
and improving cardiovascular outcomes // Open Heart. ― 2015. ―
№1. ― e000327.
34. Peng X., Zhang G., Liao Y., et al. Inhibitory kinetics and
mechanism of kaempferol on α-glucosidasе // Food Chem. ―
2016. ― №190. ― Р. 207-215.
35. O'keefe J.H., Gheewala N.M., O'keefe J.O. Dietary strategies
for improving post-prandial glucose, lipids, inflammation, and
cardiovascular health // J. Am. Coll. Cardiol. ― 2008. ― №51. ―
Р. 249-255.
36. Shimabukuro M., Higa M., Yamakawa K., et al. Miglitol,
α-glycosidase inhibitor, reduces visceral fat accumulation and
cardiovascular risk factors in subjects with the metabolic syndrome:
a randomized comparable study // Int. J. Cardiol. ― 2013. ― №5. ―
Р. 108-113.
37. Yamasaki Y. et al. Alpha-Glucosidase inhibitor reduces the
progression of carotid intima-media thickness // Diabetes Res. Clin.
Pract. ― 2005. ― №3. ― Р. 204-210.
38. Chen J.M., Chang C.W., Lin Y.C., et al. Acarbose treatment
and the risk of cardiovascular disease in type 2 diabetic patients: a
nationwide seven-year follow-up study // J. Diabetes Res. ― 2014. ―
№8. ― Р. 126-128.
39. Аметов А.С. Регуляция секреции инсулина в норме и при
сахарном диабете 2 типа: роль инкретинов // Русский Медицинский
Журнал. ― 2006. ― Т. 14, №26. ― С. 1867-1872.
40. Holst J.J., Gromada J. Role of incretin hormones in the
regulation of insulin secretion in diabetic and nondiabetic humans //
Am. J. Physiol. Endocrinol. Metab. ― 2004. ― №287. ― Р. 199-206.
41. Анциферов М.Б., Дорофеева Л.Г. Новые подходы в лечении
сахарного диабета типа 2: глюкагоноподобный пептид-1 и эксенатид
(Баета) // Фарматека. ― 2007. ― №11. ― С. 14-19.
42. Takei I., Kasatani T. Future therapy of diabetes mellitus //
Biomed Pharmacother. ― 2004. ― №58. ― Р. 578-581.
43. Nauck M.A. Glucagon ― like peptide 1 (GLP-1) in the treatment
of diabetes // Horm. Metab. Res. ― 2004. ― №36. ― Р. 852-858.
44. Анциферов М.Б., Котешкова О.М. Опыт применения инкретиномиметика
эксенатида (Баета) в лечении больных сахарным
диабетом типа 2 с ожирением // Фарматека. ― 2009. ― №3. ―
С. 32-37.
45. DeFronzo R.A., Okerson T., Viswanathan P., et al. Effects
of exenatide versus sitagliptin on postprandial glucose, insulin
and glucagon secretion, gastric emptying, and caloric intake: a
randomized, cross-over study // Curr. Med. Res. Opin. ― 2008. ―
№10. ― Р. 2943-2952.
46. Lee T.I., Kao Y.H., Chen Y.C., et al. The dipeptidyl peptidase-4
inhibitor-sitagliptin modulates calcium dysregulation, inflammation,
and PPARs in hypertensive cardiomyocytes // Int. J. Cardiol. ―
2013. ― №168. ― Р. 5390-5395.
47. Lago R.M., Singh P.P., Nesto R.W. Congestive heart failure and
cardiovascular death in patients with prediabetes and type 2 diabetes
given thiazolidinediones: a meta-analysis of randomised clinical
trials // Lancet. ― 2007. ― №370. ― Р. 1129-1136.
48. Buse J.B., Rosenstock J., Sesti G., et al. Liraglutide
once a day versus exenatide twice a day for type 2 diabetes:
a 26-week randomised, parallel-group, multinational, open-label trial
(LEAD-6) // Lancet. ― 2009. ― №374. ― Р. 39-47.
49. Rosenstock J., Baron M.A., Dejager S., et al. Comparison
of vildagliptin and rosiglitazone monotherapy in patients with type
2 diabetes: a 24-week, double-blind, randomized trial // Diabetes
Care. ― 2007. ― №30. ― Р. 217-223.
50. Okerson T., Yan P., Stonehouse A., et al. Effects of exenatide
on systolic blood pressure in subjects with type 2 diabetes // Am. J.
Hypertens. ― 2010. ― №23. ― Р. 334-339.
51. Nystrom T., Gutniak M.K., Zhang Q., et al. Effects of glucagonlike
peptide-1 on endothelial function in type 2 diabetes patients
with stable coronary artery disease // Am. J. Physiol. Endocrinol.
Metab. ― 2004. ― №287. ― Р. 1209-1215.
52. Arakawa M., Mita T., Azuma K., et al. Inhibition of monocyte
adhesion to endothelial cells and attenuation of atherosclerotic
lesion by a glucagon-like peptide-1 receptor agonist, exendin-4 //
Diabetes. ― 2010. ― №59. ― Р. 1030-1037.
53. Ban K. Cardioprotective and vasodilatory actions of glucagonlike
peptide 1 receptor are mediated through both glucagonlike
peptide 1 receptor dependent and independent pathways //
Circulation. ― 2008. ― №117. ― Р. 2340-2350.
54. Darsalia V., Ortsäter H., et al. The DPP-4 inhibitor linagliptin
counteracts stroke in the normal and diabetic mouse brain:
a comparison with glimepiride // Diabetes. ― 2013. ― №4. ―
Р. 1289-1296
55. Adamíková A. Possibilities of therapy GLP1 RA for diabetics
with nephropathy // Vnitr Lek. ― 2015. ― №4. ― Р. 312-315.
56. Green J.B. et al. Effect of Sitagliptin on Cardiovascular
Outcomes in Type 2 Diabetes // N. Engl. J. Med. ― 2015. ― №3. ―
Р. 232-242.
57. Chen D.Y. et al. Sitagliptin and cardiovascular outcomes in
diabetic patients with chronic kidney disease and acute myocardial
infarction: A nationwide cohort study // Int. J. Cardiol. ― 2015. ―
№181. ― Р. 2006.
58. Scirica B.M., Bhatt D.L., Braunwald E., et al. Saxagliptin and
cardiovascular outcomes in patients with type 2 diabetes mellitus //
N. Engl. J. Med. ― 2013. ― №369. ― Р. 1317-1326.
59. Udell J.A. at al. SAVOR-TIMI 53 Steering Committee and
Investigators Saxagliptin and cardiovascular outcomes in patients
with type 2 diabetes and moderate or severe renal impairment:
observations from the SAVOR-TIMI 53 Trial // Diabetes Care. ―
2015. ― №38. ― Р. 696-705.
60. Rosenstock J., Marx N., Neubacher D., et al. Cardiovascular
safety of linagliptin in type 2 diabetes: a comprehensive patient-level
pooled analysis of prospectively adjudicated cardiovascular events //
Cardiovasc Diabetol. ― 2015. ― №14. ― Р. 57.
61. Maeda S., Yamagishi S., Matsui T., et al. Beneficial effects of
vildagliptin on retinal injury in obese type 2 diabetic rats // Ophthalmic
Res. ―2013. ― №50. ― Р. 221-226.
62. McInnes G., Evans M., Del Prato S., et al. Cardiovascular and
heart failure safety profile of vildagliptin: a meta-analysis of 17,000
patients // Diabetes Obes. Metab. ― 2015. ― №11. ― Р. 1085-1092.
63. Nauck M.A., Del Prato S., Meier J.J., et al. Dapagliflozin versus
glipizide as add- on therapy in patients with type 2 diabetes who have
inadequete glyceamic control with metformin: a randomised, 52-
week, double-blind, active-controlled noninferiority trial // Diabetes
Care. ― 2011. ― Vol. 34. ― P. 2015-2022.
64. Basile J.N. The potential of sodium glucose cotransporter
2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with
type 2 diabetes (T2DM) // J. Diabetes Complications. ― 2013. ―
27 (3). ― P. 280–286
65. U.S. Food and Drug Administratio http://www.fda.gov/Drugs/
DrugSafety/ucm446845.htm
Современные проблемы диагностики в медицине